# OraSure Technologies, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/OraSure Technologies, Inc).

## Overview

OraSure Technologies is a U.S.-based diagnostics and specimen-collection company that develops, manufactures, markets, and sells rapid tests and related collection devices. Its portfolio includes oral-fluid and other in vitro diagnostic tests, HIV and hepatitis self-tests, and sample management products used across clinical, public health, research, and commercial settings.

## Products & services

• OraQuick® rapid HIV and HCV tests
• OraQuick® HIV Self-Test and HCV Self-Test
• InteliSwab® COVID-19 rapid test products
• Syphilis and other infectious disease tests
• Sample management and specimen collection devices
• Colli-Pee® urine collection device
• Microbiome and molecular services

- **Diagnostics - Professional** (58%) — Rapid diagnostic tests sold to healthcare and public health customers for infectious disease screening.
- **Diagnostics - Self-Test** (12%) — At-home and self-administered infectious disease tests sold through retail and distribution channels.
- **Sample Management Solutions** (25%) — Specimen collection and sample handling products for clinical, research, and commercial labs.
- **Other Products and Services** (5%) — Smaller product lines and service revenues, including research-use devices and related services.

- OraQuick® rapid HIV and HCV tests
- OraQuick® HIV Self-Test and HCV Self-Test
- InteliSwab® COVID-19 rapid test products
- Syphilis and other infectious disease tests
- Sample management and specimen collection devices
- Colli-Pee® urine collection device
- Microbiome and molecular services

## Customers

OraSure sells to a mix of public health agencies, hospitals, physician offices, clinics, distributors, and retail channels, with additional demand from laboratories and research-oriented commercial customers. Its diagnostics are used for infectious disease screening and self-testing, while sample management products are bought by clinical labs, direct-to-consumer testing providers, pharmaceutical and biotech customers, and academic or research users.

- **Public health agencies and programs** (primary) — Buy HIV, HCV, and other infectious disease tests for screening and outreach programs.
- **Hospitals, clinics, and physician offices** (primary) — Buy rapid diagnostic tests for point-of-care infectious disease testing.
- **Distributors and retail channels** (secondary) — Buy self-test products and resell them into consumer and institutional markets.
- **Clinical and direct-to-consumer laboratories** (primary) — Buy sample collection and management products for testing workflows.
- **Research, biotech, and pharmaceutical customers** (secondary) — Buy specimen collection devices and related products for studies and assay development.
- **Animal health and companion animal customers** (emerging) — Buy sample management products for veterinary and animal-health applications.

- U.S. hospitals, physician offices, and clinics buying rapid tests
- Public health agencies and government-funded testing programs
- Retail and distributor channels for self-testing products
- Clinical laboratories and direct-to-consumer testing providers
- Research, biotech, and pharmaceutical customers for sample collection

## Geography

OraSure markets products in the United States and internationally, with U.S. public health and clinical customers representing a core market. International demand is important for HIV-related products, and the company also uses distributors in certain foreign countries for selected tests and sample management products.

- **United States** — Core market for diagnostics, public health, and sample management sales
- **International** — Includes Africa, Asia, and other foreign markets served directly or via distributors

- United States is the core market for diagnostics and public health sales
- International HIV demand is important for self-tests and distributor sales
- Africa and Asia are key exposure areas for funded HIV programs
- Canada houses a meaningful portion of cash and liquidity resources
- Distributor networks extend reach in foreign markets and retail channels

## Strategy

OraSure’s strategy centers on expanding simple, easy-to-use diagnostics and specimen-collection products across professional, public health, self-test, and research channels. The company also emphasizes proprietary technologies, regulatory clearances, and distribution partnerships to support commercialization and broaden access to its products.

- **Grow self-testing and point-of-care diagnostics** (medium-term) — These products fit the company's ease-of-use positioning and broaden end-market reach.
- **Secure regulatory clearances for new products** (short-term) — FDA and other approvals are required to commercialize new diagnostic offerings.
- **Expand distributor and public health channels** (medium-term) — Distribution access is critical in fragmented diagnostics markets and international sales.
- **Develop sample management and collection products** (long-term) — These products diversify the portfolio beyond infectious disease testing.

- Expand oral-fluid and self-testing adoption
- Use regulatory clearances to support commercialization
- Broaden distribution through direct sales and partners
- Develop specimen collection products for new research uses
- Leverage proprietary technology to defend niche segments

## Risks

OraSure faces regulatory, reimbursement, and competitive risks typical of diagnostics companies, along with customer concentration and dependence on government-funded purchasing. Its results also depend on manufacturing quality, distributor execution, intellectual property protection, and continued acceptance of oral-fluid and self-testing products.

- **Regulatory approval and compliance risk** [high] — New diagnostics require FDA or other clearances, and noncompliance can halt sales or trigger recalls.
- **Government funding and ordering risk** [high] — A meaningful portion of demand depends on public programs and grant-funded customers.
- **Customer concentration** [medium] — A small number of customers can represent a disproportionate share of revenue.
- **Distributor dependence** [medium] — Third-party distributors control sales execution in several markets and geographies.
- **Competition in diagnostics** [medium] — Larger competitors have greater resources and can pressure pricing and market share.
- **Manufacturing and quality risk** [high] — Products must meet performance and regulatory standards to remain sellable.

- FDA or other approval delays can postpone product launches
- Government funding changes can reduce customer ordering
- Customer concentration can create revenue volatility
- Distributor performance affects market access and sales
- Competition and reimbursement pressure can limit adoption
- Manufacturing or quality issues can trigger recalls or lost sales

## Accounting

OraSure recognizes product revenue when control transfers to the customer, which makes shipment timing and distributor sell-through important for quarterly results. Investors should also watch estimates around warranty returns, customer allowances, contingent consideration, and impairment testing for goodwill and intangible assets, since these can materially affect reported earnings.

- **Revenue recognition for product sales** — Quarterly revenue comparability
- **Returns and warranty reserves** — Net revenue and gross margin
- **Goodwill and intangible impairment** — Earnings and balance sheet carrying values
- **Fair value of contingent consideration** — Operating results
- **Allowance and rebate estimates** — Reported net sales

- Product revenue is recognized at transfer of control
- Distributor and retail returns can affect net revenue
- Warranty accruals are based on historical experience
- Goodwill and intangibles require periodic impairment testing
- Contingent consideration and fair value estimates can move earnings

---

*Last updated: 2026-04-29T04:43:10.733331+00:00*